Jin‐Ji Yang

机构：Guangdong Academy of Medical Sciences · ORCID：0000-0002-8498-0119

发表论文 279 篇 · 总被引 9305 次 · h-index 50

代表论文

• Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial (2024 · The Lancet Oncology · 被引 105)
• Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients (2023 · Cancer Cell · 被引 103)
• Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 75)
• Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study (2023 · Signal Transduction and Targeted Therapy · 被引 45)
• PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial (2023 · 中国科学通报：英文版 · 被引 37)
• Detection of MET amplification ( MET amp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib. (2023 · Journal of Clinical Oncology · 被引 27)